Bracco Imaging Enters Cell Therapy Space with Innovative Microbubble Technology

Bracco Imaging is stepping into the cell therapy arena with its breakthrough microbubble technology, introducing a gentle, scalable method for cell selection. This move, in collaboration with partners like CellBri and Limula, positions Bracco to offer an alternative to traditional bead-based cell selection—potentially reshaping cell therapy manufacturing processes.

Having honed their expertise in diagnostic imaging for over two decades, Bracco Imaging is leveraging its robust microbubble technology to address crucial challenges in cell therapy. The proprietary lipid-based microbubbles allow for bead-free cell selection and are adaptable to a variety of immune cell subsets. This innovation not only simplifies upstream cell manufacturing processes but also introduces flexibility in positive, negative, and sequential selection strategies. Collaborations with key players and academic institutions, such as the University of Fribourg, aim to develop an automated, clean, and scalable system, marking a significant shift from conventional magnetic bead approaches.

Bracco Imaging’s venture into cell therapy with advanced microbubble technology promises to streamline manufacturing workflows and reduce costs, potentially revolutionizing the landscape of cell therapy. As the company prepares for clinical utilization by 2027, this innovative approach is poised to expand the possibilities of cell therapy manufacturing, providing developers with a versatile and efficient tool to better address industry needs.